Diabetic Polyneuropathy. New Directions for Improving the Effectiveness of Pathogenetic Therapy

The article presents modern ideas about the features of etiopathogenesis, pathomorphological causes and risk factors of diabetic polyneuropathy, describes its main forms and clinical manifestations, as well as features of diagnosis and pathogenetic therapy. The results of a study on the efficacy and safety of using Cellex in the treatment of patients with diabetic polyneuropathy are presented, which analyzed the effect of Cellex on reducing the severity and frequency of neuropathic and neurological symptoms of the disease, reducing the risk of developing neuropathic ulcers, as well as on the quality of life of patients. According to the results of the study, the use of Cellex significantly contributes to the normalization of the condition of patients with diabetic polyneuropathy, reduces the risk of developing neuropathic ulcers, and also leads to an improvement in the quality of life.